ARTIS Ventures, a firm that partners with entrepreneurs who are driven to impact their world through innovation positively, announced recently that it closed $200 million in new capital for its second fund focused on the convergence of health and medicine TechBio II. The firm said it will continue making a firm-wide commitment to TechBio and fund and support its next generation of founders and startups.
About a decade ago, when AI was emerging, it saw its opportunity to transform human health and well-being by utilizing growing data sets, advanced analytics, and insights. And over the past decade, by tapping into the power of AI, the firm’s portfolio companies have pioneered innovations across clinical medicine, medical devices, computational biology, etc, fundamentally changing the quality of care and alleviating suffering globally.
KEY QUOTE:
“At ARTIS, we’ve been fortunate over the past decade to have had a front-row seat at the accelerating convergence of frontier technologies and medicine. We have witnessed firsthand just how technological advancements in areas like artificial intelligence, machine learning, and synthetic biology have ushered in new generations of life-saving innovations and medicines. Diseases that once seemed unconquerable now have promising treatment options and even cures on the horizon. Cutting-edge companies are developing personalized therapies tailored to each patient’s unique biology, finally moving beyond a one-size-fits-all approach. We are also gaining incredible new tools to understand the body, mind, and the connections between them as never before. The expertise of medical professionals is being augmented and enhanced through these advances. And the building blocks of biology are being harnessed to develop revolutionary new therapies and solutions. We call this all-important work and its convergence ‘TechBio’ and we’re excited to continue to leverage our leadership role as a pioneer within the space to accelerate this revolution.”
- Stuart Peterson & Vasudev Bailey, Managing Partners, ARTIS Ventures
